Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Article 2015 en
Authors
MP
Marc A. Pfeffer
BC
Brian Claggett
RD
Rafael Díaz
Abstract
1 min read
In patients with type 2 diabetes and a recent acute coronary syndrome, the addition of lixisenatide to usual care did not significantly alter the rate of major cardiovascular events or other serious adverse events. (Funded by Sanofi; ELIXA ClinicalTrials.gov number, NCT01147250.).
Jelena P. Seferović, Rhonda Bentley–Lewis, Brian Claggett, Rafael Díaz, Hertzel C. Gerstein, Lars Køber, Francesca Lawson, Eldrin F. Lewis, Aldo Maggioni, John J.V. McMurray, Jeffrey L. Probstfield, Matthew C. Riddle, Scott D. Solomon, Jean-Claude Tardif, Marc A. Pfeffer
Marc A. Pfeffer, Brian Claggett, Rafael Díaz, Kenneth Dickstein, Hertzel C. Gerstein, Lars Køber, Francesca Lawson, Ping Lin, Xiaodan Wei, Eldrin F. Lewis, Aldo Maggioni, John J.V. McMurray, Jeffrey L. Probstfield, Matthew C. Riddle, Scott D. Solomon, Jean‐Claude Tardif
Hertzel C. Gerstein, Sibylle Hess, Brian Claggett, Kenneth Dickstein, Lars Køber, Aldo Maggioni, John J.V. McMurray, Jeffrey L. Probstfield, Matthew C. Riddle, Jean‐Claude Tardif, Marc A. Pfeffer
Hertzel C. Gerstein, Sibylle Hess, Brian Claggett, Kenneth Dickstein, Lars Køber, Aldo Maggioni, John J.V. McMurray, Jeffrey L. Probstfield, Matthew C. Riddle, Jean‐Claude Tardif, Marc A. Pfeffer
Magnus Wijkman, Brian Claggett, Rafael Díaz, Hertzel C. Gerstein, Lars Køber, Eldrin F. Lewis, Aldo Maggioni, Emil Wolsk, David Aguilar, Rhonda Bentley–Lewis, John J.V. McMurray, Jeffrey L. Probstfield, Matthew C. Riddle, Jean‐Claude Tardif, Scott D. Solomon, Marc A. Pfeffer
Discussion(0)
No comments yet. Be the first to comment.